All Penny Stocks (English) on MSN1d
Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgherCharting, Price Performance, News & Related Contracts.
Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.
Ardelyx is currently reviewing the District Court’s decision and will consider all options related to the lawsuit.
GlobalData on MSN23h
Arch Biopartners doses first subject in trial of acute kidney injury treatmentCanadian clinical trial company Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of ...
Recent revisions to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have potentially doubled the patient population that could benefit from Filspari. This expansion of the target ...
Q3 2024 Earnings Call Transcript October 31, 2024 Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
The updated draft KDIGO guidelines which should drive nephrologists ... and few in development for this progressive rare kidney disease. Specifically, we were very pleased that this group of ...
The primary objective of the trial is to evaluate the percentage of subjects with acute kidney injury within seven days following on-pump (heart-lung machine) cardiac surgery, as defined by the KDIGO ...
KDIGO, and the New England Journal of Medicine on the benefits of comprehensive genetic testing for patients with CKD," said Anthony Bleyer, MD, MS, professor of nephrology at Wake Forest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback